

(A joint stock limit

a

GENERAL INFORMATION

[illegible]

Sa e a d c ed ab e, a a e da e f a ce e , e be ed e a d be ef
f e D ec a ade a ea ab e e e , S a e de e ed ab a f
e e e a e a e e P e a Ac a e AGM.

A c c a c a , a e , () f e d e a f e P e a A c ;
 () a e e f e I d e e d e B a d C e e e I d e e d e S a e d e (e
 e e c e d a f e I d e e d e B a d C e e); () a e e f a d c e f
 G a C a a e I d e e d e B a d C e e a d e I d e e d e S a e d e ; () e
 e a a e ; a d () a c e f e A G M , b e b e d e e b e f e
 S c E c a e (. e e .) a d e e b e f e C a (. . c) , a d
 d a c e d e d e f H S a e f e C a a c c d a c e e c e e a f
 e c e f c a e c c a , c a c e e a c a b e L R e .

A add a e e ed f a be ce a f a be c ded e c c a ,
e C a e ec b a d/ d a c e c c a e a e e ab e
bef e 9 J e 2026.

POTENTIAL ACQUISITION

O 18 Ma 2026, e B a d c de ed a d a ed e e e a e P e a
Ac . T e C a e c a e e P e f G da I e e a a
c de a f RMB31.45 . T e P e ed be ed a a e e f eac
a d c e f c e e a c . S b e c e a a f e P e a Ac b e S a e de
a e AGM, e C a f a e e e P e P c a e A e e e G da
I e e . T e C a a e a a ce e d e c e acc da ce e
e e e f e L R e e f a e ec f e P e P c a e A e e e .
T e c a e f e P e P c a e A e e e a e a b e d a f :

Pa e : (1) e C a , a e c a e ; a d

(2) G d a I e e , a e e d .

Na e f e a ac : T e C a e a ee ac e, a d G da I e e
e a ee e , e P e , bec e e a d
c d e e P e P c a e A ee e .

The P e : The P e ca ed a F 12 15, P a e II, H e
Ed ca Pa B e Ce e , C a a S bd c , O a
D c , We C , Z e a P ce, e PRC, a
f a ea f 4,523.86 . . a d a d e a ea f 267.90
. . T e a ed e f e P e a d f acc da
a d ca e / e , a d e e f e a d e
e e 29 Ja a 2043. T e P e de e ed b G da
I e e , e ef e e a c a e c f e P e
G da I e e a cab e.

A a e a bee ce a ed e e P e , S a a
P d De e e Ba C ., L d. We B a c be e
a ee. T e af e e ed a e a be e ea ed
e e f e P e .

A a e da e f a ce e , e P e -
ed b G da I e e .

De e a d e a f U e C a f a e f e c de a de e
a fe f e: P e P c a e A ee e , e P e a be de e ed
e C a a a - ba e eed f a f a
a d e ced e . G da I e e a a e
de e e C a e ce f ca e f a d e a d
b d e , a e a e e c a e ce
e ec f e P e . T e C a a a de e e a
f a fe f e f e P e .

W effec f e da e f de e f e P e , a e
e ce- e a ed e e e a be b e b e C a , a d a
f da a e, a d a e a a be b e b
e C a .

PAYMENT TERMS AND BASIS FOR DETERMINING THE CONSIDERATION

T e a c de a f e ac f e P e RMB31.45 (c e f a).
T e c de a a de e ed af e a e e a be ee e a e ba ed e
fa a e a e, efe e ce e a a f e P e f RMB35,286,000 c d c ed b
e de e de e a e , A a-Pac f c C a d A a a L ed (e **Independent**
Valuer), ba ed e a a ed a e a e f e P e a a 30 A 2026 e
a e c a a ac . T e C a c de ef e f e a a e
e ec f e P e e c c a f e AGM. T e c a c e f e a a e
a e a f :

Valuation Date

30 A 2026

Basis of Valuation

The Independent Valuer has carried out a detailed analysis of the available data and has identified the most appropriate valuation method. The Valuer has considered the nature of the property, the availability of comparable data, and the requirements of the client. The Valuer has concluded that the most appropriate valuation method is the market comparison method.

Methods of Valuation

The Independent Valuer has carried out a detailed analysis of the available data and has identified the most appropriate valuation method. The Valuer has considered the nature of the property, the availability of comparable data, and the requirements of the client. The Valuer has concluded that the most appropriate valuation method is the market comparison method.

Valuation Assumptions

The Independent Valuer has carried out a detailed analysis of the available data and has identified the most appropriate valuation method. The Valuer has considered the nature of the property, the availability of comparable data, and the requirements of the client. The Valuer has concluded that the most appropriate valuation method is the market comparison method.

The Independent Valuer has carried out a detailed analysis of the available data and has identified the most appropriate valuation method. The Valuer has considered the nature of the property, the availability of comparable data, and the requirements of the client. The Valuer has concluded that the most appropriate valuation method is the market comparison method.

Valuation Standards

In accordance with the International Valuation Standards, the Independent Valuer has carried out a detailed analysis of the available data and has identified the most appropriate valuation method. The Valuer has considered the nature of the property, the availability of comparable data, and the requirements of the client. The Valuer has concluded that the most appropriate valuation method is the market comparison method.

Conclusion of Value

The Independent Valuer has carried out a detailed analysis of the available data and has identified the most appropriate valuation method. The Valuer has considered the nature of the property, the availability of comparable data, and the requirements of the client. The Valuer has concluded that the most appropriate valuation method is the market comparison method.

In addition, the Valuer has carried out a detailed analysis of the available data and has identified the most appropriate valuation method. The Valuer has considered the nature of the property, the availability of comparable data, and the requirements of the client. The Valuer has concluded that the most appropriate valuation method is the market comparison method.

The Valuer has carried out a detailed analysis of the available data and has identified the most appropriate valuation method. The Valuer has considered the nature of the property, the availability of comparable data, and the requirements of the client. The Valuer has concluded that the most appropriate valuation method is the market comparison method.

The academy of the people benefited by the
the C.A.

ONLINE SIGNING

Sa e a d c ed ab e, a a e da e f a ce e , e be ed e a d be ef
f e D ec a ade a ea ab e e e , S a e de e ed ab a f
e e e a e a e e P e a Ac a e AGM.

A c c a c a , a e , () f e de a f e P e a Ac ; () a
e e f e I de e de B a d C ee e I de e de S a e de (e
ec e da f e I de e de B a d C ee); () a e e f ad ce f G a Ca a
e I de e de B a d C ee a d e I de e de S a e de ; () e e a a
e ; a d () a ce f e AGM, be b ed e eb e f e S c E c a e
(. e e .) a d e eb e f e C a (. .c), a d d a c ed e
de f H S a e f e C a acc da ce e c e ea f e ce f c a e
c ca , c a ce e a cab e L R e .

A add a e e ed f a e ce a f a be c ded e c c a , e
C a e ec b a d/ d a c e c c a e a e e ab e bef e 9
J e 2026.

DEFINITIONS

I a ce e , e e c e e e e e , ef e e a a e
e f ea :

AGM e 2025 a a e e a ee f e C a be c e ed
d e c e

B a d e b a d f d ec f e C a

C a We Ka H a C ., L d. (溫州康寧醫院股份有限公
司), a c ed c a e ab ed de e a f
e PRC, e H S a e f c a e ed e a b a d f e
S c E c a e (c c de: 2120)

c ec ed e () a e ea a c bed de e L R e

c ec ed a ac () a e ea a c bed de e L R e

D ec () e d ec () f e C a

G da I e e We G da I e e C ., L d. (溫州國大投資有限公司),
a ed ab c a c a ed e PRC, e a e
be ef c a e f c M . GUAN We

H S a e () e ea ed f e a e () e a e ca a f e C a
a a a e f RMB1.00 eac , c a e ed a d aded
e a b a d f e S c E c a e

H K e H K S ec a Ad a e Re f e PRC

I de e de B a d e de e de b a d c ee c a e de e de
C ee -e ec e D ec (a e , M . ZHONG We a , M . JIN
L a d M . CHAN Sa Ke H), e ab ed ad e e
I de e de S a e de e ec f e P e a Ac

I de e de F a c a G a Ca a L ed, a ce ed c a ca e
 Ad e 6 (ad c a e f a ce) e a ed ac de e
 G a Ca a Sec e a d F e O d a ce (C a e 571 f e La f H
 K), a a ed a e I de e de F a c a Ad e ad e
 e I de e de B a d C ee a d e I de e de S a e de
 e ec f e P e a Ac

de e de -e ec e e de e de -e ec e D ec () f e C a
 D ec ()

I de e de S a e de () a e e ed ab a f a e
 S a e de () AGM e ec f e a a f e P e a Ac

L R e e R e G e e L f Sec e T e S c
 E c a e f H K L ed, a a e ded, e e ed
 e e d f e d f e e

e acc d e e e a e a f e We M c a
 G e e f Z e a P ce, e PRC, e a e a d c a e f
 c e c a e e b ec e a d f
 e e e a e e e c b e d b e e e .

PRC C a e Pe e' Re b c f C a, f e e f a ce e ,
 e c de H K , e Maca S ec a Ad a e Re f e
 PRC a d Ta a

P e P c a e e P e P c a e A ee e be e e ed be ee e
 A ee e C a a d G da I e e

P e a Ac e ed c a e f e P e b e C a f G da
 I e e

RMB e a f c e c f e PRC

SFO e Sec e a d F e O d a ce (C a e 571 f e La f
 H K), a a e ded, e e ed e e d f e d f
 e e

S a e () e a e () f e C a , c d d e c S a e () a d H
 S a e ()

S a e de () de () f e S a e ()

S c E c a e T e S c E c a e f H K L ed

. . a e e e

e P e e e ca ed a F 12 15, P a e II, H e Ed ca
Pa B e Ce e , C a a S bd c , O a D c , We
C , Z e a P ce, e PRC

ea a e() a e ea a c bed de e L R e

B e f e B a d
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili